Abstracts tagged "cytokines"

Abstract Number: 47 • 2018 ACR/ARHP Annual Meeting
Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model
Kotona Furuyama¹, Yuya Kondo¹, Masaru Shimizu², Iizuka Akira¹, Masahiro Yokosawa¹, Seiji Segawa¹, Hiroto Tsuboi¹, Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Internal Medicine, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: RORγt+Foxp3+ regulatory T (Treg) cells, designated as Tr17 is one of the new subset of Treg cells, having the potential to regulate the development…
Abstract Number: 1088 • 2018 ACR/ARHP Annual Meeting
Pro-Inflammatory and Regulatory Soluble Mediator Pathways Vary between African American and European American SLE Patients
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women, and is associated with periods of elevated and suppressed clinical symptoms. SLE…
Abstract Number: 2510 • 2018 ACR/ARHP Annual Meeting
A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Mark C. Genovese¹, Mario Berkowitz², Philip G. Conaghan³, Katherine Davy⁴, David Inman⁵, Elena Fisheleva^6,7, Anubha Gupta⁶, Robert Janiczek⁶, Mark Layton⁸, Nina Mitchell^6,7, Jatin Patel⁹, Julia E. Smith¹⁰, Russell Williamson⁵ and Paul-Peter Tak¹¹, ¹Stanford University Medical Center, Palo Alto, CA, ²Leon Medical Research, Lauderdale Lakes, FL, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Statistics, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁵GlaxoSmithKline, Stockley Park, United Kingdom, ⁶GlaxoSmithKline, Stevenage, United Kingdom, ⁷Currently at Biomarin UK Ltd, London, United Kingdom, ⁸ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁹ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ¹⁰Immunoinflammation TA, GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ¹¹GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the effects…
Abstract Number: 59 • 2018 ACR/ARHP Annual Meeting
Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model
Ruby J. Siegel¹, Solomon A. Agere¹, Anil K. Singh¹ and Salahuddin Ahmed^2,3, ¹Washington State University, Department of Pharmaceutical Sciences, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: Syndecans are cell-surface heparan sulfate proteoglycans (HSPGs) that modulate the receptor/ligand binding of chemokines, cytokines, and growth factors in order to facilitate cellular signaling.…
Abstract Number: 1335 • 2018 ACR/ARHP Annual Meeting
Extracellular Vesicles Induce Pro-Inflammatory Cytokines in Dermatomyositis
Krisha Desai^1,2, Majid Zeidi^3,4, Ming-Lin Liu^1,2 and Victoria P. Werth^1,2, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
Background/Purpose: Extracellular vesicles (EVs) are micron-scale bilayer membrane vesicles released from almost all cell types under activation or apoptosis. They have been detected in various…
Abstract Number: 2519 • 2018 ACR/ARHP Annual Meeting
Exposure-Efficacy Analysis in DMARD Inadequate Response Rheumatoid Arthritis Patients Treated with GSK3196165 Along with Methotrexate
Anubha Gupta¹, Chiara Zecchin¹, Elena Fisheleva^1,2, Mark Layton³ and Stefano Zamuner⁴, ¹GlaxoSmithKline, Stevenage, United Kingdom, ²Currently at Biomarin UK Ltd, London, United Kingdom, ³ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁴Clinical Pharmacology, GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: GSK3196165 is an anti-GM-CSF mAb being developed for RA. In a phase IIb dose-finding study (NCT02504671), RA patients with inadequate response to methotrexate were…
Abstract Number: 96 • 2018 ACR/ARHP Annual Meeting
The Liver X Receptor Modulates Inflammatory Cytokines Based on Lxrα Polymorphism in Monocyte-Derived Macrophages and Patients with Systemic Lupus Erythematosus
Chang-Hee Suh¹, Wook-Young Baek², Hyoun-Ah Kim³ and Ju-Yang Jung², ¹Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ²Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South)
Background/Purpose: Liver X receptors (LXRs) have emerged as important regulators of inflammatory gene expression. Previously, we had reported that an LXRα gene promoter polymorphism (-1830…
Abstract Number: 1476 • 2018 ACR/ARHP Annual Meeting
Implication of CXCL5 (Epithelial neutrophil-activating peptide 78) in the Development of Insulin Resistance in Patients with Rheumatoid Arthritis
Sonia Peña¹, Beatriz-Segura Tejera², Raquel Lopez-Mejías³, De Vera-González AM⁴, Alejandra Gonzalez-Delgado⁵, Miguel Angel González-Gay⁶ and Iván Ferraz-Amaro⁷, ¹Rheumatology, Servicio de Reumatología, Hospital Universitario de Canarias,Spain, La Laguna, Spain, ²Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁴Division of Central Laboratory. Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁵Division of Central Laboratory. Hospital Universitario de Canarias., Tenerife, Spain, ⁶Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, ⁷Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain
Background/Purpose: The chemokine molecule CXCL5 (C-X-C motif chemokine ligand 5, also known as epithelial neutrophil activating peptide 78 -ENA78-) constitutes a link between obesity, inflammation…
Abstract Number: 2763 • 2018 ACR/ARHP Annual Meeting
Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
Matthew J. Koster¹, Melissa Snyder², Michel Villatoro-Villar¹, Cynthia S. Crowson³, Tanaz A. Kermani⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: To investigate the utility of serum free light chains (FLC), antiphospholipid antibodies (APL), and cytokines in the evaluation of patients with biopsy-proven giant cell…
Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Majid Zeidi^1,2, Krisha Desai^3,4, Hee Joo Kim^3,4,5 and Victoria P. Werth^3,4, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)
Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…
Abstract Number: 1487 • 2018 ACR/ARHP Annual Meeting
Correlation between Cytokine Levels and Power-Doppler Ultrasound Activity Is BMI Dependent, and Different in ACPA Positive and ACPA Negative RA with Wrist Arthritis
Ottar Gadeholt¹, Erin Arnold², Corinne Gorman³, Tobias Mueller⁴ and William Arnold², ¹Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ²Orthopedics and Rheumatology of the North Shore, Skokie, IL, ³Orthopaedics & Rheumatology of the North Shore, Skokie, IL, ⁴Department of Bioinformatics, University of Wuerzburg, Wuerzburg, Germany
Background/Purpose: Multiple cytokines are assumed to be involved in RA pathogenesis. It has been hypothesized that ACPA-negative RA with wrist affection constitutes a separate entity.…
Abstract Number: 2837 • 2018 ACR/ARHP Annual Meeting
Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients
Samantha Slight-Webb¹, Joel M. Guthridge¹, Eliza Chakravarty¹, Hua Chen¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Stanford University, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Mycophenolate mofetil (MMF) is a commonly used medication to treat major organ involvement in SLE, specifically in patients with lupus nephritis. The safety and…
Abstract Number: 962 • 2017 ACR/ARHP Annual Meeting
Role of Syndecans in Cytokine Mediated Inflammation in Rheumatoid Arthritis Synovial Fibroblasts
Solomon Agere¹, Nahid Akhtar¹, David Fox² and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Department of Medicine [Division of Rheumatology], University of Michigan Medical System, Ann Arbor, MI
Background/Purpose: Syndecans (SDCs) are type-I transmembrane proteoglycans that prominently interact with heparan sulfate, extracellular matrix (ECM) components and glycoproteins. The present study was carried out…
Abstract Number: 2329 • 2017 ACR/ARHP Annual Meeting
Monocytes from Patients with Enthesitis Related Arthritis Produce High Levels of Pro-Inflammatory Cytokines: Role of Endogenous Ligands
Amita Aggarwal¹, Shruti Bhattacharya² and Ramnath Misra², ¹Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: HLA B27 and gut bacteria are postulated to play a role in pathogenesis of Enthesitis Related Arthritis. Gut microbes can activate monocytes/macrophages by TLR…
Abstract Number: 965 • 2017 ACR/ARHP Annual Meeting
Decoy Receptor 3 up-Regulates Cadherin 2 in Rheumatoid Synovial Fibroblasts
Koji Fukuda¹, Yasushi Miura^2,3, Shinya Hayashi², Toshihisa Maeda^1,4 and Ryosuke Kuroda¹, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Orthpaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ⁴Department of Immunology and Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand, LIGHT, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.